Clinical Trial Update: Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating IMAB362 (zolbetuximab) in combination with the EOX chemotherapy regimen for CLDN18.2-positive gastric, gastroesophageal junction, and e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagus
• Adenocarcinoma of the Gastroesophageal Junction
• Gastric Adenocarcinoma

Drugs mentioned

• ELLENCE (Epirubicin hydrochloride)
• Eloxatin (oxaliplatin)
• IMAB362 (zolbetuximab)
• Xeloda (capecitabine)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus | Phase 2 | Status: COMPLETED